FAQ: How Do You Balance Systemic and Liver Directed Therapies in Patients With MASH?
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
FAQ: How Do You Balance Systemic and Liver Directed Therapies in Patients With MASH?
-
Narrated by:
-
Written by:
About this listen
Thank you Madrigal for your support on this FAQ Video Module.
In this FAQ video, Allysa Saggese, NP, reviews how clinicians can balance systemic and liver-directed therapies in the treatment of metabolic dysfunction–associated steatohepatitis (MASH) and shares insights on the evolving role of combination therapy. The discussion explores current guideline-aligned options, including GLP-1–based systemic therapies and liver-directed agents, and emphasizes individualized treatment decisions based on fibrosis stage, metabolic comorbidities, patient preferences, and access considerations. Designed for APPs and clinicians, this overview highlights why multimodal therapy—alongside lifestyle interventions like diet and exercise—is likely the future of MASH management.